Dr. Harish Guddati, M.D
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,834 | 75 | 95.3% |
| Gift | $89.99 | 1 | 4.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $731.53 | 37 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $284.59 | 10 | $0 (2024) |
| Celgene Corporation | $265.94 | 18 | $0 (2024) |
| Gilead Sciences Inc | $250.00 | 2 | $0 (2017) |
| Valeant Pharmaceuticals North America LLC | $123.57 | 2 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $100.00 | 1 | $0 (2017) |
| Boston Scientific Corporation | $40.00 | 1 | $0 (2019) |
| Shionogi Inc | $29.31 | 1 | $0 (2019) |
| Celltrion USA Inc. | $28.88 | 1 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $26.86 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $424.73 | 19 | ABBVIE INC. ($227.38) |
| 2023 | $428.99 | 25 | ABBVIE INC. ($222.33) |
| 2022 | $439.67 | 21 | ABBVIE INC. ($260.07) |
| 2021 | $87.62 | 4 | Celgene Corporation ($39.01) |
| 2019 | $69.31 | 2 | Boston Scientific Corporation ($40.00) |
| 2017 | $473.57 | 5 | Gilead Sciences Inc ($250.00) |
All Payment Transactions
76 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $23.65 | General |
| Category: IMMUNOLOGY | ||||||
| 11/06/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $30.21 | General |
| Category: IMMUNOLOGY | ||||||
| 11/06/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $0.78 | General |
| Category: IMMUNOLOGY | ||||||
| 10/31/2024 | Celltrion USA Inc. | VEGZELMA (Biological) | Food and Beverage | In-kind items and services | $28.88 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $29.76 | General |
| Category: INTERNAL MEDICINE | ||||||
| 08/07/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $31.25 | General |
| Category: INTERNAL MEDICINE | ||||||
| 07/23/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $23.62 | General |
| Category: IMMUNOLOGY | ||||||
| 06/26/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $25.89 | General |
| Category: IMMUNOLOGY | ||||||
| 05/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $28.71 | General |
| Category: IMMUNOLOGY | ||||||
| 05/01/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $26.04 | General |
| Category: INTERNAL MEDICINE | ||||||
| 04/17/2024 | ABBVIE INC. | HUMIRA (Biological), RINVOQ | Food and Beverage | In-kind items and services | $21.00 | General |
| Category: IMMUNOLOGY | ||||||
| 04/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $2.32 | General |
| Category: IMMUNOLOGY | ||||||
| 04/04/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $22.67 | General |
| Category: Immunology | ||||||
| 03/07/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $26.33 | General |
| Category: IMMUNOLOGY | ||||||
| 02/28/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $27.17 | General |
| Category: INTERNAL MEDICINE | ||||||
| 02/21/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $16.86 | General |
| Category: Neuroscience | ||||||
| 02/07/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $16.13 | General |
| Category: IMMUNOLOGY | ||||||
| 01/24/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.72 | General |
| Category: Neuroscience | ||||||
| 01/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $28.74 | General |
| Category: IMMUNOLOGY | ||||||
| 12/06/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $16.70 | General |
| Category: Neuroscience | ||||||
| 11/15/2023 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $28.43 | General |
| Category: IMMUNOLOGY | ||||||
| 11/01/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $26.59 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/19/2023 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $16.53 | General |
| Category: IMMUNOLOGY | ||||||
| 10/04/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $17.06 | General |
| Category: Neuroscience | ||||||
| 10/04/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $1.71 | General |
| Category: Neuroscience | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 459 | 525 | $697,015 | $61,242 |
| 2022 | 11 | 466 | 531 | $578,828 | $60,173 |
| 2021 | 12 | 436 | 492 | $550,087 | $55,692 |
| 2020 | 11 | 355 | 393 | $385,994 | $36,701 |
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 87 | 141 | $91,650 | $15,252 | 16.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 104 | 107 | $123,035 | $12,714 | 10.3% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 49 | 49 | $157,270 | $11,087 | 7.0% |
| 43246 | Insertion of stomach tube using a flexible endoscope | Facility | 2023 | 20 | 20 | $52,755 | $3,879 | 7.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 26 | 26 | $24,685 | $3,687 | 14.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 35 | 41 | $21,180 | $3,221 | 15.2% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 48 | 48 | $130,210 | $3,189 | 2.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 25 | 28 | $18,140 | $2,949 | 16.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 33 | 33 | $58,150 | $2,790 | 4.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 20 | $10,700 | $1,400 | 13.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 12 | 12 | $9,240 | $1,074 | 11.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 91 | 137 | $89,050 | $15,129 | 17.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 82 | 83 | $95,438 | $10,500 | 11.0% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 37 | 37 | $104,340 | $9,210 | 8.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 48 | 61 | $35,075 | $5,804 | 16.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 27 | 27 | $25,860 | $4,387 | 17.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 42 | 43 | $67,080 | $3,811 | 5.7% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 43 | 43 | $101,910 | $3,474 | 3.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 44 | 47 | $21,150 | $3,420 | 16.2% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 25 | 25 | $22,250 | $2,357 | 10.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 15 | 16 | $8,560 | $1,079 | 12.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 12 | 12 | $8,115 | $1,001 | 12.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 61 | 77 | $49,630 | $9,236 | 18.6% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 32 | 32 | $90,240 | $7,226 | 8.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 54 | 54 | $62,092 | $6,962 | 11.2% |
About Dr. Harish Guddati, M.D
Dr. Harish Guddati, M.D is a Student in an Organized Health Care Education/Training Program healthcare provider based in Bronx, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/14/2012. The National Provider Identifier (NPI) number assigned to this provider is 1891040911.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Harish Guddati, M.D has received a total of $1,924 in payments from pharmaceutical and medical device companies, with $424.73 received in 2024. These payments were reported across 76 transactions from 12 companies. The most common payment nature is "Food and Beverage" ($1,834).
As a Medicare-enrolled provider, Guddati has provided services to 1,716 Medicare beneficiaries, totaling 1,941 services with total Medicare billing of $213,808. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Location Bronx, NY
- Active Since 07/14/2012
- Last Updated 07/14/2012
- Taxonomy Code 390200000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1891040911
Products in Payments
- RINVOQ (Biological) $436.67
- ZEPOSIA (Drug) $292.80
- ENTYVIO (Biological) $284.59
- Epclusa (Drug) $250.00
- SKYRIZI (Biological) $183.89
- HUMIRA (Biological) $110.97
- ZEPATIER (Drug) $100.00
- ORCAPOD (Device) $40.00
- XIFAXAN (Drug) $33.58
- Mulpleta (Drug) $29.31
- VEGZELMA (Biological) $28.88
- OMVOH (Drug) $22.67
- AMJEVITA (Biological) $20.54
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in Bronx
Dr. David Altschul, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $394,687
Edvard Skripochnik, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $127,559
Dr. Cynthia Armand
Student in an Organized Health Care Education/Training Program — Payments: $68,024
Dr. Eric Woods, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $40,336
Ms. Kavita Gupta, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $31,772
Dr. Dmitriy Nevelev, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $30,107